Phaseline

Companies › THPharm

THPharm: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 4 Phase 3, 1 Phase 2, 1 Phase 1; Cardiovascular, Neurology, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dapagliflozin (THP-00101)
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 3Type 2 DiabetesDec 2026
Telmisartan (THP-00102)
Type-1 angiotensin II receptor antagonist
AGTR1Phase 3Type 2 Diabetes; Parkinsons Disease (PD); Ovarian Cancer; Prostate CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06647745Dapagliflozin (THP-00101)Phase 3Type 2 DiabetesCardiovascularDec 2026
NCT06647745Telmisartan (THP-00102)Phase 3Type 2 DiabetesCardiovascularDec 2026
NCT06647745Telmisartan (THP-00102)Phase 3Type 2 DiabetesCardiovascularDec 2026
NCT06168487Telmisartan (THP-00102)Phase 1Prostate CancerOncologyApr 2027
NCT06815497Telmisartan (THP-00102)Phase 2Ovarian CancerOncologyApr 2027
NCT07207057Telmisartan (THP-00102)Phase 3Parkinsons Disease (PD)NeurologyMay 2031

Targets

SLC5A2 (1) AGTR1 (1)

Companies with the same targets

Boryung Pharmaceutical AstraZeneca Lexicon Pharmaceuticals Getz Pharma Boehringer Ingelheim Dong-A ST Hangzhou Zhongmei Huadong Pharmaceutical JW Pharmaceutical HB BioTech Chong Kun Dang Pharmaceutical

Companies built like this

Shin Poong Pharmaceutical Shenzhen Ausa Pharmed iVascular S.L.U. CSPC Mingfule Pharmaceutical (Guangzhou) Pulmovant

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.